Meiragtx looks to a phase III in Parkinson’s - Cure Parkinson's

Cure Parkinson's

26,493 members27,905 posts

Meiragtx looks to a phase III in Parkinson’s

Farooqji profile image
2 Replies

Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, double-blind, sham controlled trial of AAV-GAD, a one-time infusion, demonstrated significant and clinically meaningful improvements in key efficacy endpoints. The primary objective was evaluating the therapy’s safety and tolerability. The study of participants with idiopathic disease showed the therapy was safe and well-tolerated with no serious adverse events. Meiragtx is pursuing approvals in the U.S., Europe and Japan.

bioworld.com/articles/71352...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
michelagvolpe profile image
michelagvolpe

but this was made on 2012

clinicaltrials.gov/study/NC...

Not what you're looking for?

You may also like...

Bummer. Isradipine fails in Phase III Trial.

Long-term use of blood pressure medication Dynacirc (isradipine) does not slow disease progression...
jimcaster profile image

Phase 2 Mesenchymal Stem Cell Trial in USA

"A newly opened Phase 2 clinical trial is evaluating adult stem cells as a potentially...
jimcaster profile image

Phase III Inosine Trial to Slow Parkinson's Now Recruiting around The United States

This is one of the few possible neuroprotective trials for early stage Parkinson's and they are...
p-oui profile image

Nicotinamide riboside supplement shows promise as a potential therapy for Parkinson’s disease - I started taking it today!

Nicotinamide riboside supplement shows promise as a potential therapy for Parkinson’s disease...